30mg Librela Solution for Dogs – 2 Vials

Description

30mg Librela is an innovative drug for the alleviation of pain associated with osteoarthritis in dogs.

Librela 30mg innovative solution uses monoclonal antibodies to target and neutralize Nerve Growth Factor (NGF), a leading cause of osteoarthritis pain. By working differently from NSAIDs, Librela offers a month-long relief from pain with minimal involvement of liver or kidneys and with few GI side effects.

Each vial of 1ml Librela contains 30mg bedinvetmab. Librela is a caninised monoclonal antibody.

Librela is used for the alleviation of pain associated with osteoarthritis in Dogs.

Dosage and administration
Librela is for subcutaneous use. The recommended dose of Librela is 0.5-1.0 mg/kg bodyweight, once a month.

For dogs weighing <5.0 kg aseptically withdraw 0.1 ml/kg from a single 5 mg/ml vial and administer subcutaneously. For dogs between 5 and 60 kg administer the entire content of the vial (1ml) according to the dose prescribed by your Vet. For dogs above 60 kg, the contents of more than one vial are required to administer a single dose. In those cases, withdraw the content from each required vial into the same syringe and administer as a single subcutaneous injection (2ml).

Contra-indications, warnings, etc.
Do not use Librela in cases of hypersensitivity to the active substance or to any of the excipients. Do not use Librela in dogs under 12 months. Do not use Librela in animals intended for breeding. Do not use Librela in pregnant or lactating animals.